NEM vs STRO · P/E 14, rev $22.67B vs rev $62.0M
Newmont Goldcorp Corp (NEM) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Newmont Goldcorp Corp (NEM) is a gold company listed on NYSE.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported NEM revenue for 2025-12-31 was $22.67B. Net income was $7.08B. Revenue was up 21.3% from 2024-12-31 to 2025-12-31. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
NEM currently screens at market cap $112.81B and trailing P/E 13.7. STRO currently screens at market cap $470.8M.
Not investment advice. Open the NEM and STRO stock pages for the full models.
Not investment advice.